Story perspectives

Eli Lilly to Spend $3.8 B on Three Vaccine Makers

5/27/2026

Summary

Eli Lilly Acquires

On May 26 2026, Eli Lilly announced it will buy three vaccine firms—Curevo for $1.5 billion, LimmaTech for $780 million and Vaccine Company for $1.55 billion—totaling up to $3.83 billion.
Curevo’s amezosvatein shingles vaccine matched immunity in Phase 2 and halved side effects.
LimmaTech’s LTB-SA7 for Staphylococcus aureus and Vaccine Company’s EBV vaccine are in Phase 1 trials.
Chief scientific officer Daniel Skovronsky said the deals aim to prevent disease using cash from obesity and diabetes drugs.

Summary

Lilly Acquires Vaccine

Eli Lilly’s acquisition of Vaccine Company positions it to launch the first-ever Epstein-Barr virus vaccine, directly challenging Moderna’s later-stage EBV effort.
The amezosvatein shingles candidate’s lower side-effect profile could boost patient uptake compared with GSK’s Shingrix vaccine.
Lilly’s move into preventive immunizations shifts its focus from chronic-disease drugs toward disease-prevention strategies.
Entry into the vaccine market may reshape Lilly’s competitive standing as global demand for preventive therapies expands.

Summary

Lilly Expands Portfolio

Lilly's acquisition push proceeds under Health Secretary Robert F. Kennedy Jr., whose policies are hostile to vaccine development.
The deals were announced as the regulatory environment under U.S. President Donald Trump creates uncertainty for vaccine approvals.
Lilly hired Dr. Peter Marks, former FDA top vaccine regulator, to guide its new infectious-disease portfolio.
In 2026 Lilly's acquisition spending topped $20 billion and aligned with AI-driven drug discovery partnerships valued up to $2.75 billion.

Summary

Lilly Raises Outlook

Eli Lilly raised its full-year 2026 revenue outlook to $82-$85 billion after announcing the vaccine acquisitions.
The company also lifted non-GAAP earnings-per-share guidance to $35.50-$37.00.
Shares rose 1.36% to $1,079.19 by 11:56 a.m. ET, up from $1,065 at Friday’s close.
GLP-1 obesity and diabetes drugs produced $49.329 billion, roughly 58% of Lilly’s $84.978 billion 2025-Q1 2026 revenue, providing cash for the deals.

History

Historical Context

In 2009 Pfizer finalized a $68 billion purchase of Wyeth, instantly adding a strong vaccine pipeline that boosted its sales. The deal followed Pfizer’s earlier 2000 hostile bid for Warner-Lambert, which secured its position as a top-ranked drug company. Today, the acquisition is cited as a model for large-scale vaccine purchases shaping industry strategy.

1 of 5

Eli Lilly Acquires

On May 26 2026, Eli Lilly announced it will buy three vaccine firms—Curevo for $1.5 billion, LimmaTech for $780 million and Vaccine Company for $1.55 billion—totaling up to $3.83 billion.
Curevo’s amezosvatein shingles vaccine matched immunity in Phase 2 and halved side effects.
LimmaTech’s LTB-SA7 for Staphylococcus aureus and Vaccine Company’s EBV vaccine are in Phase 1 trials.
Chief scientific officer Daniel Skovronsky said the deals aim to prevent disease using cash from obesity and diabetes drugs.

1 / 5